

Athens, 2 May 2020

Dear Editor WJH,

Thank you for considering our manuscript for publication in *World Journal of Hepatology*. We also thank the reviewers for their thoughtful comments, which have been extremely helpful for the final improvement of our manuscript. Please find below the changes that we have made to our initial submission in response to the reviewers' recommendations.

Reviewer # 1

Thank you for your comments

Reviewer # 2

Point 1. Recently, there are several review papers focusing on the role of glucagon-like peptide-1 receptor agonists in NAFLD and NASH. Please acknowledge their contributions and your novelty. Various metabolism disorders, including thyroid function (PMID: 30224316), are associated with the occurrence of NAFLD. In the Introduction section, please do not forget their role.

Although there are some reviews regarding this topic, we have focused only on GLP-1 agonists (in both animal and clinical studies) and we have managed to critically update the literature data, since there are new studies during the last 2-3 years. In addition, we have not found any mini-review on GLP-1/NAFLD published recently by WJH or other journal published by the Baishideng Publishing Group.

Thank you for your comment regarding thyroid function. We totally agree. We had mentioned in the revised version this issue in introduction section

Point 2. *Various types of glucagon-like peptide-1 receptor agonists have their own mechanisms. So it is important to briefly and clearly outline their own advantages and disadvantages for NAFLD in conclusion section.*

Thank you again for this comment. In the conclusions, we have emphasized more and critically evaluated literature data regarding the main advantages and disadvantages of GLP-1 receptor agonists

Point 3. *Lixisenatide and Dulaglutide paragraphs are too short compared to the Exenatide paragraph. I suggest to expand their animal studies. Grammar and spelling errors should be carefully revised, such as "... showed a improvement in ...".*

There are limited data regarding the effects of lixisenatide and dulaglutide on NAFLD. We found only one animal study, while we added another clinical study (Ref 40 and 43, respectively).

Point 4. *Grammar and spelling errors should be carefully revised, such as "... showed a improvement in ...".*

We have corrected now some English errors. Thank you

Sincerely,

Evangelos Cholongitas, MD, MSc, PhD